Literature DB >> 15002635

Evidence-based and value-based formulary guidelines.

Peter J Neumann1.   

Abstract

Health plans and hospitals have long used drug formularies, but the processes by which formulary committees made decisions have typically lacked transparency and scientific rigor. A growing number of organizations have begun implementing formulary guidelines issued by the Academy of Managed Care Pharmacy (AMCP). These guidelines call for health plans to request formally that drug companies present a standardized "dossier" that contains detailed information not only on the drug's effectiveness and safety but also on its economic value relative to alternative therapies. This paper describes the guidelines, reviews progress to date, and analyzes several critical issues for the future.

Mesh:

Year:  2004        PMID: 15002635     DOI: 10.1377/hlthaff.23.1.124

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  14 in total

1.  Principles for evidence-based drug formulary policy.

Authors:  Gregory E Simon; Bruce M Psaty; Jennifer Berg Hrachovec; Marc Mora
Journal:  J Gen Intern Med       Date:  2005-10       Impact factor: 5.128

2.  Rates and probabilities in economic modelling: transformation, translation and appropriate application.

Authors:  Rachael L Fleurence; Christopher S Hollenbeak
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

3.  Measuring preferences for cost-utility analysis: how choice of method may influence decision-making.

Authors:  Christine M McDonough; Anna N A Tosteson
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 4.  Economic evaluation in the US: what is the missing link?

Authors:  Peter J Neumann; Sean D Sullivan
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

5.  Reform of prescription drug reimbursement and pricing in the German social health insurance market: a comparison of three scenarios.

Authors:  Stefan Gress; Dea Niebuhr; Uwe May; Jürgen Wasem
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

6.  The increasingly complex fourth hurdle for pharmaceuticals.

Authors:  Joshua Cohen; Elly Stolk; Maartje Niezen
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

7.  Does the funding source influence the results in economic evaluations? A case study in bisphosphonates for the treatment of osteoporosis.

Authors:  Rachael L Fleurence; D Eldon Spackman; Christopher Hollenbeak
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

8.  Pharmacy Benefit Management Companies: Do They Create Value in the US Healthcare System?

Authors:  Alan Lyles
Journal:  Pharmacoeconomics       Date:  2017-05       Impact factor: 4.981

Review 9.  Economics of atypical antipsychotics in bipolar disorder: a review of the literature.

Authors:  Rachael L Fleurence; Julia M Dixon; Dennis A Revicki
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

10.  Cost effectiveness analysis for nursing research.

Authors:  Mark E Bensink; Linda H Eaton; Megan L Morrison; Wendy A Cook; R Randall Curtis; Deborah B Gordon; Anjana Kundu; Ardith Z Doorenbos
Journal:  Nurs Res       Date:  2013 Jul-Aug       Impact factor: 2.381

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.